Kallikrein 4 (hK4) and prostate-specific antigen (PSA) are associated with the loss of E-cadherin and an epithelial-mesenchymal transition (EMT)-like effect in prostate cancer cells

T L Veveris-Lowe^{1,2*}, M G Lawrence^{1*}, R L Collard^{1*}, L Bui¹, A C Herington¹, D L Nicol^{2,3} and J A Clements^{1,2}

¹School of Life Sciences and Science Research Centre, Queensland University of Technology, Brisbane, Australia

²Wesley Research Institute, Brisbane, Australia

³Department of Urology, Princess Alexandra Hospital, Brisbane, Australia

(Requests for offprints should be addressed to J Clements, Prostate Cancer Research Program, School of Life Sciences, Queensland University of Technology, GPO Box 2434, Brisbane, 4001, Australia; Email: j.clements@qut.edu.au)

* (T L Veveris-Lowe, M G Lawrence and R L Collard contributed equally to this work)

Abstract

Prostate-specific antigen (PSA) and the related kallikrein family of serine proteases are current or emerging biomarkers for prostate cancer detection and progression. Kallikrein 4 (*KLK4*/hK4) is of particular interest, as *KLK4* mRNA has been shown to be elevated in prostate cancer. In this study, we now show that the comparative expression of hK4 protein in prostate cancer tissues, compared with benign glands, is greater than that of PSA and kallikrein 2 (*KLK2*/hK2), suggesting that hK4 may play an important functional role in prostate cancer progression in addition to its biomarker potential. To examine the roles that hK4, as well as PSA and hK2, play in processes associated with progression, these kallikreins were separately transfected into the PC-3 prostate cancer cell line, and the consequence of their stable transfection was investigated. PC-3 cells expressing hK4 had a decreased growth rate, but no changes in cell proliferation were observed in the cells expressing PSA or hK2. hK4 and PSA, but not hK2, induced a 2.4-fold and 1.7-fold respective increase, in cellular migration, but not invasion, through Matrigel, a synthetic extracellular matrix. We hypothesised that this increase in motility displayed by the hK4 and PSA-expressing PC-3 cells may be related to the observed change in structure in these cells from a typical rounded epithelial-like cell to a spindle-shaped, more mesenchymal-like cell, with compromised adhesion to the culture surface. Thus, the expression of E-cadherin and vimentin, both associated with an epithelial-mesenchymal transition (EMT), was investigated. E-cadherin protein was lost and mRNA levels were significantly decreased in PC-3 cells expressing hK4 and PSA (10-fold and 7-fold respectively), suggesting transcriptional repression of E-cadherin, while the expression of vimentin was increased in these cells. The loss of E-cadherin and associated increase in vimentin are indicative of EMT and provides compelling evidence that hK4, in particular, and PSA have a functional role in the progression of prostate cancer through their promotion of tumour cell migration.

Endocrine-Related Cancer (2005) 12 631–643

Introduction

Prostate cancer is now the most frequently diagnosed cancer in men, excluding skin cancers (Jemal *et al.*

2004). In 2004, it was expected to contribute to 33% of all newly diagnosed cancers and 10% of estimated cancer deaths in the USA (American Cancer Society 2004, Jemal *et al.* 2004). Prostate-specific antigen

(PSA), also known as kallikrein 3 (*KLK3/hK3*), is a serine protease secreted by normal and malignant prostatic epithelial cells and is the current serum biomarker for prostate cancer (Partin *et al.* 2002a,b). Kallikrein 2 (*KLK2/hK2*) is also emerging as a useful adjunct marker clinically, particularly in the discrimination of benign and malignant disease in the PSA 4–10 ng/ml range, as well as in organ-confined disease (Haese *et al.* 2001, 2003). Although less widely studied, kallikrein 4 (*KLK4/hK4*) is also highly expressed by the prostate epithelium and is increased in prostate cancer at the mRNA level, suggesting a similar biomarker potential (Obiezu *et al.* 2002, Xi *et al.* 2004). Most research has focused principally on the clinical utility of the prostate-specific kallikreins, but much less is known about their biological role in prostate cancer progression. In this context, the kallikreins have been implicated in the degradation of extracellular matrix (ECM) molecules, the processing of growth factors to their active forms (or inactivation of their regulators) and the activation of other enzymes, including other kallikreins, implicated in prostate cancer (Borgono & Diamandis 2004, Clements *et al.* 2004).

Epithelial-mesenchymal transition (EMT) is a crucial event in the progression of cancer to an invasive phenotype. The perturbation of E-cadherin and increased expression of vimentin are two currently accepted characteristics associated with EMT. E-cadherin is downregulated in most epithelial cancers, and can be correlated to higher mobility and invasiveness of tumour cells (Hirohashi & Kanai 2003). The change in E-cadherin expression observed in many prostate cancer cases can be attributed to methylation of the E-cadherin promoter (Kallakury *et al.* 2001) or truncation of the protein leading to its inactivation (Davies *et al.* 2001). In contrast, vimentin expression is usually increased in cells which have undergone EMT and has been characterised in migrating cancer cells (Hendrix *et al.* 1997, Gilles *et al.* 1999, Singh *et al.* 2003). Vimentin is associated with increased *in vitro* motility of prostate cancer cell lines, and immunohistochemical studies have shown elevated levels of vimentin in the majority of advanced prostate cancer tissues and bone metastases (Lang *et al.* 2002).

In this study, we sought to determine the relative expression levels of hK4, compared with the more well-known PSA and hK2, and to determine its involvement in biological processes associated with cancer progression. We have unequivocally shown, for the first time, a clearly increased expression of hK4, at the protein level, in cancer compared with benign tissues. This observation not only shows that hK4 is more cancer specific in expression than PSA or hK2 – thus

having potential as a useful diagnostic/prognostic biomarker for prostate cancer – but also suggests that hK4 may play an important functional role in prostate cancer progression. To elucidate such a role, we have characterised PC-3 cells transfected separately with the three prostate-specific kallikreins, *KLK4*, *KLK3/PSA* and *KLK2*. We report that the expression of hK4 and PSA, but not hK2, promotes cell migration and alters the structure of these cells. E-cadherin expression is lost, while vimentin expression is increased, both hallmarks of EMT-like behaviour. These findings suggest that the prostatic kallikreins, hK4 and PSA, may play a role in the initiation of EMT-like changes in prostate cancer cells and thus are important modulators of prostate cancer progression.

Materials and methods

Immunohistochemistry

Formalin-fixed paraffin blocks from prostate tumours ($n=6$) and benign prostatic hyperplasia (BPH) ($n=6$) were sectioned (4 μ m), deparaffinised and rehydrated. After H₂O₂ treatment to quench endogenous peroxidase, the sections were incubated overnight with an anti-PSA polyclonal antibody (1:5000 dilution; Dako, Botany, NSW, Australia), anti-hK2 monoclonal antibody (1:700 dilution; clone HK1G 586.1; Hybritech, San Diego, CA, USA), or anti-hK4 polyclonal antibody (1:250 dilution) at 4 °C respectively. The EnVision⁺ peroxidase polymer detection system (Dako) was used with 3,3'-diaminobenzidine (DAB; Sigma, Castle Hill, NSW, Australia) as the chromogen. The sections were counterstained with Mayer's haematoxylin. Normal goat serum (10%) replaced the primary antibodies as a negative control. The hK4 peptide antibody was generated by immunisation of New Zealand rabbits using a peptide, IIN-GEDCSPHSQ, designed to the NH₂-terminal region of hK4. The production, specificity and characterisation of the hK4 antibody is described elsewhere (Harvey *et al.* 2003).

Cell lines, expression plasmids and transfection

PC-3 and LNCaP prostate cancer cell lines (American Type Culture Collection, Rockville, MD, USA), were maintained in RPMI 1640 medium supplemented with 10% fetal bovine serum (FBS), 2 mM L-glutamine, 100 units/ml penicillin G sodium and 100 μ g/ml streptomycin sulphate. For transfection, the entire coding region (pre-pro-enzyme) of *KLK4*, *KLK3* or *KLK2* cDNA was amplified from mRNA extracted

from LNCaP cells and inserted into the mammalian expression vector, pcDNA3.1 (Invitrogen, Mt Waverley, Victoria, Australia). PC-3 cells, which do not express *KLK3* or *KLK2* and express low levels of *KLK4* endogenously, were transfected with the individual plasmids (pcDNA3.1:*KLK4*, pcDNA3.1:*KLK3* or pcDNA3.1:*KLK2*) or an empty vector plasmid (pcDNA3.1:vector only), using the lipid-mediated Lipofectamine 2000 Reagent protocol (Invitrogen). Stably transfected cells were selected in medium containing 100 µg/ml G418 (Invitrogen) and are denoted as PC-3:hK4 (nos. 1–6), PC-3:PSA (nos. 1–7), PC-3:hK2 (nos. 1–7) or PC-3:vector only (nos. 1 and 2) cell lines.

Western blot analysis

Western blotting was performed with cell lysates collected from several cell clones, while conditioned medium was collected after serum starvation for 48 h and concentrated 20-fold. Total protein concentrations were measured by the micro-bicinchoninic assay (BCA; Pierce, Progen, Darra, Queensland, Australia) with BSA standards. An amount of 10 µg protein samples was separated on 8–12% SDS polyacrylamide gels under denaturing conditions, transferred onto nitrocellulose membranes (Schleicher and Schuell; Medos, Mount Waverley, Victoria, Australia) and stained with Ponceau S (Sigma) to ensure that transfer and equal loading had occurred. Membranes were quenched with 5% skim milk blocking solution before primary antibodies were added and incubated at 4 °C overnight. Primary antibodies were as follows: hK2–HK1G 586.1 (Hybritech, San Diego, CA, USA), PSA–PSM 773.3.3 (Hybritech) and hK4–NH₂-terminal peptide antibody. Horseradish peroxidase-conjugated goat antimouse (hK2 and PSA) or goat antirabbit (hK4) secondary antibodies (Pierce) were applied before the addition of West Femto substrate (Pierce), chemiluminescent exposure to radiographic film and development with a Curix 60 automatic developer (Agfa, Stafford, Queensland, Australia).

RT-PCR and real-time PCR

Total RNA was extracted with TRI-Reagent (Sigma). cDNA was synthesised using Superscript II (Invitrogen), and RT-PCR and real-time PCR were performed with primers specific to the gene of interest (see figure legends). Real-time PCR was performed on an ABI 7000 Thermal Cycler using the SYBR Green I Dye detection system (Applied Biosystems, Scoresby, Victoria, Australia). Relative levels of gene expression were normalised to 18S ribosomal RNA. Each sample

was amplified three times in triplicate. Statistical analysis was performed with Student's *t*-test.

Immunofluorescence and confocal microscopy

Cells were grown on sterile 8- or 16-well glass chamber slides (Medos). Double labelling for actin (tetramethyl rhodamine isothiocyanate (TRITC)-conjugated phalloidin) and vinculin (clone 7F9) was performed with an actin cytoskeleton and focal adhesion staining kit (Chemicon, Boronia, Victoria, Australia). Tubulin was detected with the clone 2G10 antibody (Upstate Biotechnology, Auspep, Parkville, Victoria, Australia). Antibodies against E-cadherin (HECD-1 (extracellular domain) and 4A2C7 (intracellular domain); Zymed, Gynea, NSW, Australia) and vimentin (LN6; Sigma) were used for immunofluorescence. Secondary incubations were performed with AlexaFluor 488 goat anti-mouse immunoglobulin (Ig)G antibody (Molecular Probes, Bioscientific, Gynea, NSW, Australia). A Leitz fluorescent compound microscope and/or a Leica TCS 4D confocal microscope were used for imaging.

MTT cell proliferation assay

MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) proliferation assays were based on a reported method (Mosmann 1983), with modifications. All cell line clones were used in this assay and assessed every 24 h for a total of 96 h. Experiments were assayed with 18–24 replicates and repeated three times. Statistical analysis was determined at 96 h by Student's *t*-test.

In vitro motility and Matrigel invasion assays

Cell motility was determined by a reported procedure (Saito *et al.* 1997). PC-3 cell lines (5×10^4) were seeded onto 8 µm pore tissue culture inserts (Falcon, BD Biosciences, North Ryde, NSW, Australia) in serum-free medium containing 0.1% BSA, and allowed to migrate toward the chemoattractant (20% FCS) for 24 h (hK4-expressing cells) or 48 h (PSA- and hK2-expressing cells). Invasion assays were performed as for the motility assays but with growth factor-reduced Matrigel (BD Biosciences) coated on the upper surface of the insert. All assays were performed in duplicate on four occasions, with proliferation over the experimental period taken into account. Statistical analysis was performed by one-way ANOVA with Tukey's post hoc analysis.

Figure 1 Immunohistochemical staining for hK4, PSA and hK2 in benign prostatic hyperplasia (BPH) and prostate cancer tissue specimens. (A and B) hK4 staining. (C and D) PSA staining. (E and F) hK2 staining. PIN: prostatic intraepithelial neoplasia.

Results

Immunohistochemistry of kallikrein expression in prostatic tissues

To validate the previous reports of increased hK4 mRNA in prostate cancer, we first determined the relative expression levels of hK4 (protein) compared with PSA and hK2 in cancer and benign glands. This was done by immunohistochemistry, and the results shown in Fig. 1 (A–F) are representative of the staining patterns observed for all BPH ($n=6$) and prostate cancer ($n=6$) tissue sections. As expected, hK4, PSA and hK2 expression was primarily localised to the

cytoplasm of epithelial cells in both benign and cancer glands. Weak staining was observed in the epithelium of the benign glands stained with the hK4 peptide antibody, whereas strong immunoreactivity was found in the cancerous glands (Fig. 1A and B). As previously reported (Darson *et al.* 1997), the intensity of PSA staining was decreased in prostate cancer in comparison with the BPH tissue sections (Fig. 1C and D). hK2 immunostaining was slightly increased in cancer tissues, again as previously reported (Darson *et al.* 1999), particularly when compared with the PIN lesion (Fig. 1E and F). No staining was seen in the negative controls (data not shown).

These data provide the first evidence that hK4 protein is more abundant in prostate cancer tissue than in benign tissue and raise the question of its cancer-related functional role.

Establishment of an *in vitro* kallikrein expression model in stably transfected PC-3 cells

In order to examine the possible functional effects of hK4 in prostate cancer, we established an *in vitro* expression model in which PC-3 cells were stably transfected with expression constructs for either *KLK4*, *KLK3* or *KLK2*. PC-3 cells were chosen for this study because they express little or no PSA, hK2 or hK4. RT-PCR analysis confirmed that the clones transfected with *KLK4*, *KLK3* or *KLK2* were all positive for the expression of their specific genes (Fig. 2A). The native PC-3 cells and vector-only clones were appropriately negative, although low levels of endogenous *KLK4* expression were detected in these cells. Western blotting also showed that hK4, PSA and hK2 protein was overexpressed in the cell lysate and, as typical of these serine proteases, secreted into the medium when compared with the control native or vector-only cells (Fig. 2B). All clones were analysed for changes in proliferation rates, while a selection of clones (asterisked in Fig. 2A) were chosen for the other functional assays.

Morphology and phenotype of kallikrein-expressing PC-3 cells

After stable transfection, both the hK4- and PSA-expressing PC-3 cells displayed an elongated/irregular morphology (Fig. 2C). In contrast, cells transfected with the pcDNA3.1:*KLK2* or pcDNA3.1:vector-only constructs were similar in structure to the native PC-3 cell line, which had a rounded shape and formed tightly adherent colonies typical of an epithelial, cobblestone appearance.

Subcellular staining of microtubules (green) and actin filaments (red) in each cell line (Fig. 3A) confirmed the small, rounded shape in the majority of native PC-3 cells and those transfected with the empty-vector or pcDNA3.1:*KLK2* constructs. The appearance of hK4- and PSA-expressing cell lines was quite distinct from the control cell lines, particularly in the prevalence of small, actin-rich filopodia/microspikes (Fig. 3A; indicated by arrows). More extensive lamellipodia/membrane ruffling (indicated by asterisks) can be observed in these cells than in the native, vector control or hK2-expressing cell lines. Cells with lamellipodia also had classical tubulin

staining – dense within the cell body and weak in the lamella (Fig. 3A).

Furthermore, it was noted that the *KLK4*- and PSA-transfected PC-3 cells had compromised adhesion to the culture surface, did not display significant cell-to-cell contacts and did not grow in distinct colonies. Staining for vinculin (green) and actin (red) (Fig. 3B) confirmed these findings in that the native, vector-only and hK2-expressing PC-3 cell lines revealed distinct focal adhesions with actin and vinculin colocalising to the outer edges of the cell (Fig. 3B; arrowheads). Less concentrated regions of colocalisation were detected in the cells expressing hK4 and PSA.

Cell proliferation is decreased in hK4-expressing PC-3 cells, but not altered in PSA- or hK2-expressing cells

In three independent assays, the proliferation of the hK4-expressing PC-3 clones was decreased 2-fold at 96 h ($P < 0.01$) when compared with the parent PC-3 cells (Fig. 4A). No change in the proliferation rate of the PSA- or hK2-expressing clones was observed when compared with control cells at the conclusion of the experimental period.

hK4 and PSA expression in PC-3 cells promotes cell motility, but not cell invasion

None of the prostatic kallikreins expressed in the PC-3 cells significantly induced *in vitro* invasion through Matrigel compared with the control cell lines (Fig. 4B). In contrast, hK4-transfected PC-3 cells had increased motility at 24 h in comparison with the PC-3 native cells (2.4-fold increase, $P < 0.01$) and vector-only controls (2.9-fold increase, $P < 0.01$) (Fig. 4C). PSA expression in PC-3 cells induced a 2.7-fold increase in motility compared with the vector-only control cell lines ($P < 0.01$) and a 1.7-fold increase in motility compared with the PC-3 native cells at 48 h ($P < 0.01$) (Fig. 4D). Although no change in motility was seen for the hK2-expressing cells compared with the native cells, there was an increase in migration compared with the vector-only controls, but this was not significant. Interestingly, it is noted that the hK4-expressing cells migrated significantly faster (within 24 h) than PC-3 cells expressing PSA and hK2 (measured over 48 h).

Expression of E-cadherin is decreased in response to hK4 and PSA expression in PC-3 cells

These findings suggested that an EMT-like event may have occurred; therefore, the cells were analysed for

Figure 2 (A) RT-PCR analysis (PCR primers in parentheses) for *KLK4* (forward (for): 5'-atggccacagcaggaaatccc-3', reverse (rev): 5'-caaggccctgcaagtaccg-3'), *KLK3/PSA* (for: 5'-atcgaattcgaccggagagctgtgt-3', rev: 5'-ctgagggtgaactgcgcacac-3'), *KLK2* (for: 5'-tgaagcatcaaaccttagac-3', rev: 5'-ctcagactaagctctagcacac-3'), and β_2 -microglobulin housekeeping gene (for: 5'-tgaattgctatgtgtctgggt-3', rev: 5'-cctccatgatgctgcttacat-3'). All clones expressing *KLK4* (nos. 1–6), *KLK3/PSA* (nos. 1–7), *KLK2* (nos. 1–7), an untransfected/native PC-3 control (lane 1) and two different vector-only cell lines (nos. 1 and 2) (lanes 2 and 3) were analysed. Transfected clones used for functional analysis are indicated by asterisk. (B) Western blots for hK4, PSA and hK2 on representative PC-3 clones, using cell lysates (CL) and conditioned medium (CM). Each panel includes cell lysates from two control cell lines (N: PC-3 native; V1: PC-3:vector-only (no. 1)). (C) Phase-contrast micrographs of the PC-3 native cells and representatives of the PC-3:vector-only (no. 1), PC-3:hK4 (no. 5), PC-3:PSA (no. 7) and PC-3:hK2 (no. 1) clones.

Figure 3 (A) Representative clones from the native PC-3 cells, PC-3:vector-only (no. 1), PC-3:hK2 (no. 4), PC-3:hK4 (no. 6) and PC-3:PSA (no. 4), illustrating merged confocal images of tubulin (green) and actin (red) staining. Lamellipodia/membrane ruffles are indicated by asterisk, while arrows denote filopodia/microspikes. (B) Representative confocal images of cells stained for vinculin (green) and actin (red). Prominent areas of colocalisation are indicated by arrowheads. Major lamellipodia at the leading edge of PC-3:hK4 (no. 5) and PC-3:PSA (no. 3) cells are indicated by asterisk.

changes in E-cadherin and vimentin, key markers of epithelial and mesenchymal phenotypes respectively (Savanger 2001). Little or no E-cadherin staining was observed in the hK4- and PSA-expressing cells with an antibody (HECD-1) specific to the E-cadherin ecto-domain, while typical patterns of membrane staining at cell–cell contacts were observed in the control cell lines and cells expressing hK2 (Fig. 5A). Identical patterns

of expression were found with a second antibody directed to the intracellular domain of E-cadherin (4A2C7; data not shown), indicating that the entire E-cadherin protein was lost from the hK4- and PSA-expressing cell lines. This suggests that the downregulation of E-cadherin may be transcriptional. Real-time PCR analysis for E-cadherin gene expression showed a highly significant 7-fold decrease in

Figure 4 (A) Proliferation assay: graph of the mean data generated from three separate proliferation experiments and averaged for each clone type. Statistical significance was analysed by Student's *t*-test. (B) Matrigel invasion assay: fold changes for PSA-, hK2- and hK4-expressing PC-3 cells compared with the PC-3 native cells (set at 1) and vector-only controls ($n=4$, 48 h). (C) Motility assay: fold changes for hK4-expressing PC-3 cells compared with the PC-3 native (set at 1) and vector-only controls ($n=3$, 24 h). (D) Motility assay: fold changes for PSA- and hK2-expressing cells compared with the PC-3 native (set at 1) and vector-only controls ($n=4$, 48 h). All motility and invasion assays were performed with 5×10^4 cells per well, in duplicate. Statistical analysis was performed by one-way ANOVA and Tukey's post hoc analysis; S.E.M. are indicated by bars. *Statistically significant difference from controls ($P<0.01$).

PSA-expressing clones and a 10-fold decrease for hK4-expressing clones (Fig. 5B) compared with the PC-3 native cell line ($P<0.01$) and the vector-only controls ($P<0.05$). No change was seen in the hK2-expressing cells compared with the control cell lines ($P=0.14$). As expected for an EMT event, increased staining of vimentin was evident in the cells exhibiting a decrease in E-cadherin (Fig. 5A). These results were confirmed by real-time PCR, demonstrating that vimentin gene expression was elevated in PSA-expressing clones (3.7-fold; $P<0.01$) and PC-3 cells expressing hK4 (2.3-fold) (Fig. 5B), although this increase for hK4 did not reach statistical significance ($P=0.27$). Again, there was no significant change in the non-EMT-like, hK2-expressing cells.

Discussion

The immunohistochemical data presented here have established, for the first time, that hK4 protein is more highly expressed in cancer tissues than benign tissues. We have shown that hK4 is localised to the cytoplasm of glandular epithelial cells, using an

NH₂-terminal peptide antibody, which detects full-length hK4. This is consistent with previous reports suggesting that the mRNA levels for *KLK4* are increased in prostate cancer tissues (Obiezu *et al.* 2002, Xi *et al.* 2004) and strongly implicating hK4 as a possible diagnostic/prognostic marker in the progression of prostate cancer. One study has reported no change in hK4 protein, immunohistochemically, in prostate cancer tissues compared with benign tissues (Obiezu *et al.* 2002), but it is unclear how many samples were analysed in this report, and this finding could not be confirmed in our study. Both PSA and hK2 are being used clinically as diagnostic markers for prostate cancer (Borgono & Diamandis 2004, Clements *et al.* 2004) despite their recognised shortcomings. The addition of hK4 as an adjunct biomarker deserves further testing and consideration.

Strikingly, the data presented here also implicate hK4 and PSA, but not hK2, in an epithelial-mesenchymal transition (EMT) process in prostate cancer cells. EMT is a critical event in the progression of most cancers, as epithelial cells lose their characteristic phenotype and dedifferentiate (Thiery 2002).

A

B

Figure 5 (A) Representative immunofluorescence images of PC-3 cells stained for E-cadherin (with HECD-1 extracellular domain antibody) and vimentin in the control cell lines, PC-3 native and PC-3 vector-only (no. 1), and PC-3:hK2 (no. 1), PC-3:hK4 (no. 5) and PC-3:PSA (no. 3) cells. The negative control for untransfected PC-3 cells is shown. (B) Real-time PCR for E-cadherin (forward (for): 5'-gccatttctctaaaaactgg-3', reverse (rev): 5'-ttgatgacacagcgtgagag-3') and vimentin (for: 5'-aacacctgcgaatcttc-3', rev: 5'-ccatttctctcatattc-3'), using the PCR primers indicated in parentheses on PC-3 vector-only (nos. 1 and 2), PC-3:PSA (nos. 3, 4 and 7), PC-3:hK2 (nos. 1 and 4) and PC-3:hK4 (nos. 3, 5 and 7) cell lines, performed in triplicate. Gene expression was normalised to 18S ribosomal RNA (for: 5'-ttcgaaactgaggccatgat-3', rev: 5'-cgaacctccgacttcgttc-3' primers). All assays were analysed by Student's t-test. S.E.M.s are indicated by bars. *Statistically significant difference from native PC-3 cells. (*P* values E-cadherin: native vs hK4/PSA = *P*<0.01; vectors vs hK4/PSA = *P*<0.05; hK2, *P*=0.14. *P* values vimentin: native vs PSA = *P*<0.01; native vs hK4, *P*=0.27.)

Specifically, migrating epithelial cells often appear spindle-shaped, with loss of cell polarity, reduced cell-cell adhesion and rearrangement of the cytoskeleton (Savanger 2001, Thiery 2002). Observations about the functional effects of these kallikreins are based on the altered morphology and increased motility displayed by the hK4- and PSA-expressing, but not hK2-expressing, PC-3 cells with a concomitant decrease in E-cadherin and increase in vimentin, two

well-known EMT markers of epithelial and mesenchymal origin respectively (Savanger 2001).

Although increased levels of serum PSA are associated with metastatic cancer, it is now well documented that PSA gene and protein expression in prostatic cells decreases as tumours become more aggressive and increasingly undifferentiated (Darson *et al.* 1997, 1999, Tremblay *et al.* 1997). The reasons for this loss of PSA expression within malignant cells are

unclear. Of interest, while the proven metastasis-promoting gene, hepsin, has been associated with overexpression in prostate cancer tissues (Klezovitch *et al.* 2004, Stephan *et al.* 2004), its expression has been reported to be lower or even lost in metastatic cancer, suggesting that these genes could exert their effects in the early stages of invasive carcinoma rather than at the metastatic lesion (Vasioukhin 2004). We propose that this may be the case for PSA in prostate cancer progression with a subsequent loss of effects such as the suggested putative antiangiogenic and apoptotic roles (Balbay *et al.* 1999, Fortier *et al.* 1999, 2003), which would prevail in the normal functioning of the prostate. Contrary to the immunologic pattern presented by PSA in malignancy, we and several others have observed increased *KLK2/hK2* and *KLK4/hK4* expression in prostatic tumours (Herrala *et al.* 2001, Xi *et al.* 2004). This might suggest that hK4 and hK2 are more highly associated with malignancy than PSA. Furthermore, our migration studies have indicated that while PSA increased motility in PC-3 cells over 48 h, the cells expressing hK4 migrated significantly faster, suggesting that hK4 may be more important than PSA in the motility of cancer cells and ultimately cancer progression.

PC-3 cells were chosen for this study because they express little or no PSA, hK2 or hK4, unlike LNCaP cells. Although PC-3 cells also do not express α -catenin (Morton *et al.* 1993), a protein associated with linkage of E-cadherin to the actin cytoskeleton, other molecules, such as vinculin, have been shown to take the place of α -catenin, thereby allowing re-establishment of functional, cadherin-mediated cell adhesion (Hazan *et al.* 1997). Functional consequences of E-cadherin perturbations have also been reported in DU145 prostate cancer cells (Chunthapong *et al.* 2004), despite the variable expression of α -catenin in this cell line. Nonetheless, since E-cadherin was completely lost from the hK4- and PSA-expressing PC-3 cells, post-translational modifications and/or the lack of α -catenin are unlikely to be the mechanisms involved in the transcriptional decrease of E-cadherin mRNA and subsequent loss of protein.

As serine proteases, the kallikreins serve post-translationally to cleave specific polypeptide precursors to their bioactive forms, thereby indirectly initiating a range of cellular responses (Borgono & Diamandis 2004, Clements *et al.* 2004). This study has indicated that such changes may include growth regulation and EMT. A role for prostatic kallikreins in growth regulation has been predicated on the basis of *in vitro* biochemical analyses of PSA, hK2 and hK4. For instance, all three kallikreins have been shown to

degrade insulin-like growth (IGF) factor-binding proteins (IGFBPs) (Clements *et al.* 2004, Matsumura *et al.* 2004). This may then increase the bioavailability of the IGFs and therefore their mitogenic action in the prostate microenvironment. From these findings, PSA has been suggested to contribute to cancer cell growth, but, consistent with the findings of Denmeade *et al.* (2003), this was not demonstrated in our study. Furthermore, hK4 decreased PC-3 cell proliferation in this study, suggesting that it may not have a proliferative role, but instead may activate inhibitors of mitogenic factors or increase apoptosis.

Although it is unclear what level of active protease is secreted by these cells, since chromogenic substrate analysis was inconclusive (data not shown), a number of factors involved in the EMT process are known kallikrein substrates. Increasing levels of transforming growth factor (TGF) β in patients with metastatic prostate cancer have been correlated with the expression of PSA in serum (Adler *et al.* 1999). The latent (pro-) form of TGF β is known to be activated by PSA (Killian *et al.* 1993) and, by prediction, also by hK4 (Matsumura *et al.* 2004). TGF β has a number of recognised effects on prostate cancer cells, including activation of cytoskeletal modulators, such as the GTPase, RhoA (Bhowmick *et al.* 2001), and thus rearrangement of the actin cytoskeleton and induction of cell migration. TGF β can also downregulate E-cadherin expression through the transcription factors, Snail and Slug, and promote hypermethylation of the E-cadherin gene, leading to loss of the epithelial phenotype (Savanger 2001, Thiery 2002).

PSA can also activate epidermal growth factor (EGF) (Clements *et al.* 2004), which can increase cell motility by altering cell polarisation and morphology in fibroblasts (Ware *et al.* 1998). EGF (Unlu & Leake 2003a), as well as TGF β (Unlu & Leake 2003b), can upregulate urokinase plasminogen activator (uPA) expression and the invasive ability of prostate cancer cells. Recombinant hK4 and hK2 have also been shown to activate the precursor of single-chain uPA (Takayama *et al.* 2001). Thus, although PC-3 cells intrinsically produce high levels of uPA, this enzyme is unlikely to be the primary mechanism for PSA- or hK4-induced EMT. First, the EMT-like phenotype is not induced by hK2, a known activator of uPA; second, PSA does not activate uPA (Frenette *et al.* 1997), yet it induces EMT; third, neither PSA nor hK4 induced the PC-3 cells to invade through artificial ECM *in vitro* above the control cell lines; and, finally, no EMT-like effect was observed in the vector-only controls.

In summary, we have developed *in vitro* expression models for the prostatic kallikreins, PSA, hK2 and

hK4. Characterisation of the phenotype and genotype of these cells clearly indicates, for the first time, that hK4, as well as PSA, has properties that facilitate the progression of prostate cancer cells by modulating regulators of the cytoskeleton and cellular adhesion and migration processes, all hallmarks of the EMT-like processes indicative of aggressive disease.

Acknowledgements

We thank Dr Tracey Harvey for preparing the pcDNA3.1:KLK4 construct and Dr Christina Theodoropolous for assistance with confocal microscopy. We also wish to thank Stephen Mikolajczyk (Beckman Coulter Inc, San Diego, CA, USA) for the gift of the research-use anti-hk2 monoclonal antibody.

Funding

This work was supported by the National Health and Medical Research Council of Australia (grant no. 101202). T Veveris-Lowe and R Collard received Wesley Research Institute and Queensland Cancer Fund postgraduate scholarships respectively. The authors declare that there is no conflict of interest that would prejudice the impartiality of this scientific work.

References

- Adler HL, McCurdy MA, Kattan MW, Timme TL, Scardino PT & Thompson TC 1999 Elevated levels of circulating interleukin-6 and transforming growth factor-beta1 in patients with metastatic prostatic carcinoma. *Journal of Urology* **161** 182–187.
- American Cancer Society 2004 Cancer statistics presentation download www.cancer.org/docroot/pro/content/pro_1_1_Cancer_Statistics_2004_presentation.asp.
- Balbay MD, Juang P, Llansa N, Williams S, McConkey D, Fidler IJ & Pettaway CA 1999 Stable transfection of human prostate cancer cell line PC-3 with prostate-specific antigen induces apoptosis both *in vivo* and *in vitro*. *Proceedings of the American Association for Cancer Research* **40** 225–226.
- Bhowmick NA, Ghiassi M, Bakin A, Aakre M, Lundquist CA, Engel ME, Arteaga CL & Moses HL 2001 Transforming growth factor-beta1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism. *Molecular Biology of the Cell* **12** 27–36.
- Borgono CA & Diamandis EP 2004 The emerging roles of human tissue kallikreins in cancer. *Nature Reviews. Cancer* **4** 876–890.
- Chunthapong J, Seftor EA, Khalkhali-Ellis Z, Seftor REB, Amir S, Lubaroff DM, Heidger PM & Hendrix MJC 2004 Dual roles of E-cadherin in prostate cancer invasion. *Journal of Cellular Biochemistry* **91** 649–661.
- Clements JA, Willemsen NM, Myers SA & Dong Y 2004 The tissue kallikrein family of serine proteases: functional roles in human disease and potential as clinical biomarkers. *Critical Reviews in Clinical Laboratory Sciences* **41** 265–312.
- Darson MF, Pacelli A, Roche P, Rittenhouse HG, Wolfert RL, Young CY, Klee GG, Tindall DJ & Bostwick DG 1997 Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. *Urology* **49** 857–862.
- Darson MF, Pacelli A, Roche P, Rittenhouse HG, Wolfert RL, Saeid MS, Young CY, Klee GG, Tindall DJ & Bostwick DG 1999 Human glandular kallikrein 2 expression in prostate adenocarcinoma and lymph node metastases. *Urology* **53** 939–944.
- Davies G, Jiang WG & Mason MD 2001 Matrilysin mediates extracellular cleavage of E-cadherin from prostate cancer cells: a key mechanism in hepatocyte growth factor/scatter factor-induced cell–cell dissociation and *in vitro* invasion. *Clinical Cancer Research* **7** 3289–3297.
- Denmeade SR, Litvinov I, Sokoll LJ, Lilja H & Isaacs JT 2003 Prostate-specific antigen (PSA) protein does not affect growth of prostate cancer cells *in vitro* or prostate cancer xenografts *in vivo*. *The Prostate* **56** 45–53.
- Diamandis EP, Yousef GM, Clements J, Ashworth LK, Yoshida S, Egelrud T, Nelson PS, Shiosaka S, Little S, Lilja H, Stenman UH, Rittenhouse HG & Wain H 2000 New nomenclature for the human tissue kallikrein gene family. *Clinical Chemistry* **46** 1855–1858.
- Fortier AH, Nelson BJ, Grella DK & Holaday JW 1999 Antiangiogenic activity of prostate-specific antigen. *Journal of the National Cancer Institute* **91** 1635–1640.
- Fortier AH, Holaday JW, Liang H, Dey C, Grella DK, Holland-Linn J, Vu H, Plum SM & Nelson BJ 2003 Recombinant prostate specific antigen inhibits angiogenesis *in vitro* and *in vivo*. *The Prostate* **56** 212–219.
- Frenette G, Tremblay RR, Lazure C & Dube JY 1997 Prostatic kallikrein hK2, but not prostate-specific antigen (hK3), activates single-chain urokinase-type plasminogen activator. *International Journal of Cancer* **71** 897–899.
- Gilles C, Polette M, Zahm JM, Tournier JM, Volders L, Foidart JM & Birembaut P 1999 Vimentin contributes to human mammary epithelial cell migration. *Journal of Cell Science* **112** (Pt 24) 4615–4625.
- Haese A, Graefen M, Steuber T, Becker C, Pettersson K, Piironen T, Noldus J, Huland H, Lilja H & Huland E 2001 Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml. *The Prostate* **49** 101–109.
- Haese A, Graefen M, Becker C, Noldus J, Katz J, Cagiannos I, Kattan M, Scardino PT, Huland E, Huland H & Lilja H

- 2003 The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer. *The Prostate* **54** 181–186.
- Harvey TJ, Dong Y, Bui L, Jarrott R, Walsh T & Clements JA 2003 Production and characterization of antipeptide kallikrein 4 antibodies. Use of computer modeling to design peptides specific to kallikrein 4. *Methods in Molecular Medicine* **81** 241–254.
- Hazan RB, Kang L, Roe S, Borgen PI & Rimm DL 1997 Vinculin is associated with the E-cadherin adhesion complex. *Journal of Biological Chemistry* **272** 32448–32453.
- Hendrix MJ, Seftor EA, Seftor RE & Trevor KT 1997 Experimental co-expression of vimentin and keratin intermediate filaments in human breast cancer cells results in phenotypic interconversion and increased invasive behavior. *American Journal of Pathology* **150** 483–495.
- Herrala AM, Porvari KS, Kyllonen AP & Vihko PT 2001 Comparison of human prostate specific glandular kallikrein 2 and prostate specific antigen gene expression in prostate with gene amplification and overexpression of prostate specific glandular kallikrein 2 in tumor tissue. *Cancer* **92** 2975–2984.
- Hirohashi S & Kanai Y 2003 Cell adhesion system and human cancer morphogenesis. *Cancer Science* **94** 575–581.
- Jemal A, Tiwari RC, Murray T, Ghafoor A, Samuels A, Ward E, Feuer EJ & Thun MJ 2004 Cancer statistics, 2004. *CA: A Cancer Journal for Clinicians* **54** 8–29.
- Kallakury BV, Sheehan CE, Winn-Deen E, Oliver J, Fisher HA, Kaufman RP Jr & Ross JS 2001 Decreased expression of catenins (alpha and beta), p120 CTN, and E-cadherin cell adhesion proteins and E-cadherin gene promoter methylation in prostatic adenocarcinomas. *Cancer* **92** 2786–2795.
- Killian CS, Corral DA, Kawinski E & Constantine RI 1993 Mitogenic response of osteoblast cells to prostate-specific antigen suggests an activation of latent TGF-beta and a proteolytic modulation of cell adhesion receptors. *Biochemical and Biophysical Research Communications* **192** 940–947.
- Klezovitch O, Chevillet J, Mirosevich J, Roberts RL, Matusik RJ & Vasioukhin V 2004 Hepsin promotes prostate cancer progression and metastasis. *Cancer Cell* **6** 185–195.
- Lang SH, Hyde C, Reid IN, Hitchcock IS, Hart CA, Bryden AA, Vilette JM, Stower MJ & Maitland NJ 2002 Enhanced expression of vimentin in motile prostate cell lines and in poorly differentiated and metastatic prostate carcinoma. *The Prostate* **52** 253–263.
- Matsumura M, Bhatt AS, Andress D, Clegg N, Takayama TK, Craik CS & Nelson PS 2005 Substrates of the prostate-specific serine protease prostate/KLK4 defined by positional-scanning peptide libraries. *The Prostate* **62** 1–13.
- Morton RA, Ewing CM, Nagafuchi A, Tsukita S & Isaacs WB 1993 Reduction of E-cadherin levels and deletion of the alpha-catenin gene in human prostate cancer cells. *Cancer Research* **53** 3585–3590.
- Mosmann T 1983 Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. *Journal of Immunological Methods* **65** 55–63.
- Obiezu CV, Soosaipillai A, Jung K, Stephan C, Scorilas A, Howarth DH & Diamandis EP 2002 Detection of human kallikrein 4 in healthy and cancerous prostatic tissues by immunofluorometry and immunohistochemistry. *Clinical Chemistry* **48** 1232–1240.
- Partin AW, Hanks GE, Klein EA, Moul JW, Nelson WG & Scher HI 2002a Prostate-specific antigen as a marker of disease activity in prostate cancer. I. *Oncology (Huntington)* **16** 1024–1038.
- Partin AW, Hanks GE, Klein EA, Moul JW, Nelson WG & Scher HI 2002b Prostate-specific antigen as a marker of disease activity in prostate cancer. II. *Oncology (Huntington)* **16** 1218–1224.
- Saito K, Oku T, Ata N, Miyashiro H, Hattori M & Saiki I 1997 A modified and convenient method for assessing tumor cell invasion and migration and its application to screening for inhibitors. *Biological and Pharmaceutical Bulletin* **20** 345–348.
- Savanger P 2001 Leaving the neighborhood: molecular mechanisms involved during epithelial-mesenchymal transition. *BioEssays* **23** 912–923.
- Singh S, Sadacharan S, Su S, Beldegrun A, Persad S & Singh G 2003 Overexpression of vimentin: role in the invasive phenotype in an androgen-independent model of prostate cancer. *Cancer Research* **63** 2306–2311.
- Stephan C, Yousef GM, Scorilas A, Jung K, Jung M, Kristiansen G, Hauptmann S, Kishi T, Nakamura T, Loening SA & Diamandis EP 2004 Hepsin is highly over expressed in and a new candidate for a prognostic indicator in prostate cancer. *Journal of Urology* **171** 187–191.
- Takayama TK, McMullen BA, Nelson PS, Matsumura M & Fujikawa K 2001 Characterization of hK4 (protease), a prostate-specific serine protease: activation of the precursor of prostate specific antigen (pro-PSA) and single-chain urokinase-type plasminogen activator and degradation of prostatic acid phosphatase. *Biochemistry* **40** 15341–15348.
- Thiery JP 2002 Epithelial-mesenchymal transitions in tumour progression. *Nature Reviews. Cancer* **2** 442–454.
- Tremblay RR, Deperthes D, Tetu B & Dube JY 1997 Immunohistochemical study suggesting a complementary role of kallikreins hK2 and hK3 (prostate-specific antigen) in the functional analysis of human prostate tumors. *American Journal of Pathology* **150** 455–459.
- Unlu A & Leake RE 2003a The effect of EGFR-related tyrosine kinase activity inhibition on the growth and invasion mechanisms of prostate carcinoma cell lines. *International Journal of Biological Markers* **18** 139–146.

- Unlu A & Leake RE 2003*b* Transforming growth factor beta1 stimulates urokinase plasminogen activator system on prostate cancer cells. *International Journal of Biological Markers* **18** 147–151.
- Vasioukhin V 2004 Hepsin paradox reveals unexpected complexity of metastatic process. *Cell Cycle* **3** 1394–1397.
- Ware MF, Wells A & Lauffenburger DA 1998 Epidermal growth factor alters fibroblast migration speed and directional persistence reciprocally and in a matrix-dependent manner. *Journal of Cell Science* **111** 2423–2432.
- Xi Z, Klok TI, Korkmaz K, Kurys P, Elbi C, Risberg B, Danielsen H, Loda M & Saatcioglu F 2004 Kallikrein 4 is a predominantly nuclear protein and is overexpressed in prostate cancer. *Cancer Research* **64** 2365–2370.